Found 10 articles for: "Halobetasol"

Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion With a Ceramide-Containing Moisturizer in Adults With Psoriasis

February 2024 | Volume 23 | Issue 2 | | 50 | Copyright © February 2024

Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene

March 2023 | Volume 22 | Issue 3 | | 247 | Copyright © March 2023

Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion

February 2023 | Volume 22 | Issue 2 | | 132 | Copyright © February 2023

Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans. Because topical treatments are commonly used for pl...
Read More

An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis

November 2021 | Volume 20 | Issue 11 | | 1191 | Copyright © November 2021

Up to 80% of individuals with plaque psoriasis have scalp involvement, which can have a significant impact on the quality of life of affected individuals. Despite advancements in psoriasis therapeutic...
Read More

Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%–5% Affected Body Surface Area

August 2021 | Volume 20 | Issue 8 | | 829 | Copyright © August 2021

Introduction: Patients with psoriasis and low body surface area (BSA) involvement often experience substantially reduced quality of life and may be candidates for topical therapies. F...
Read More

Successful Treatment of Lichen Amyloidosis Using a Fixed Combination of Halobetasol-Propionate and Tazarotene Lotion

March 2021 | Volume 20 | Issue 3 | | 336 | Copyright © March 2021

Read More

Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants

March 2021 | Volume 20 | Issue 3 | | 252 | Copyright © March 2021

Background: Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups. Two phase 3 stud...
Read More

Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials

October 2018 | Volume 17 | Issue 10 | | 1062 | Copyright © October 2018

BACKGROUND: Topical corticosteroids (TCS) are the mainstay of psoriasis treatment; long-term safety concerns limiting con...
Read More

Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination

August 2018 | Volume 17 | Issue 8 | | 863 | Copyright © August 2018

Background: Psoriasis is a chronic condition often managed with topical therapy. Patients have high expectations about the speed at which ...
Read More

Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy

July 2018 | Volume 17 | Issue 7 | | 723 | Copyright © July 2018

Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS...
Read More